Kano

Kano Therapeutics is a pioneering biotechnology company focused on developing single-stranded DNA (ssDNA) solutions to enhance gene editing technologies. Operating in the genomic engineering market, Kano serves scientists, research labs, and biotech companies by providing optimized DNA donor materials that complement CRISPR and other gene editing tools. The company employs a fermentation-based DNA production method, which is cost-effective and scalable, to produce gene-length circular ssDNA templates. This approach combines the stability of double-stranded DNA with the flexibility of RNA, offering superior therapeutic nucleic acids. Kano's business model revolves around the production and sale of these ssDNA materials, as well as the development of a unique databank linking ssDNA sequence design to activity, which accelerates development timelines and reduces costs for partners. Founded by Dr. Floris Engelhardt, a PhD in Physics with a focus on DNA nanotechnology, Kano is committed to advancing genetic cures while maintaining environmental stewardship.

Keywords: ssDNA, gene editing, CRISPR, genomic engineering, biotechnology, DNA donors, fermentation-based production, therapeutic nucleic acids, cost-effective, scalable.